CompaniesHalioDx

HalioDx

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

0

As Collaborator

4

Total Enrollment

1,272

By Phase

NA: 1

By Status

UNKNOWN: 3WITHDRAWN: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
NCT03422601
NCT03946033
NCT05422547
NCT05900583
Hover over trial bars to see details

Recent Trials

NCT05900583Collaborator
Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
N/AUnknown
50 participants
Started: Jun 1, 2023 · Completed: Aug 31, 2025
NCT05422547Collaborator
Role of Immunoscore® in Stage II-III Colorectal Cancer
N/AUnknown
100 participants
Started: Apr 1, 2022 · Completed: Dec 30, 2023
NCT03946033Collaborator
Impact of Immunoscore Colon Test on Adjuvant Therapeutic Strategy in Non-Metastatic Colon Cancer
NAWithdrawn
Started: May 31, 2019 · Completed: Feb 28, 2021
NCT03422601Collaborator
Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment
N/AUnknown
1,122 participants
Started: Jul 13, 2017 · Completed: Jul 15, 2019
Related Companies
Veracyte
acquired